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The neutral endopeptidase NEP 24.11 (enkephalinase) has been visualized in human spinal cord by in vitro 
autoradiography using [‘HIHACBO-Gly as a radiolabelled probe. The specific binding was present in the 
substantia gelatinosa and particularly dense in meninges surrounding the spinal cord. Enzymatic studies 
using [3H][D-Ala2,Leu]enkephalin as substrate confirmed the presence of NEP in dura and pia mater of 
human tissue. In addition, the human meninges were shown to contain high concentrations of angiotensin- 
converting enzyme (ACE) and aminopeptidases. The three enzymes have also been detected in rat tissues 
but their distribution pattern differs from that of human tissue. In dura mater, 45 $ of the [Leulenkephalin 
hydrolysis was due to enkephalinase and 38 % to bestatin-sensitive aminopeptidases. In contrast in pia mater 
aminopeptidases were more efficient in hydrolyzing enkephalin. The possible role of these nzymes in the 
meninges could be to maintain the homeostatic concentration of neuropeptides in the central nervous 
system. 
Enkephalin; Enkephalinase; Angiotensin-converting enzyme; Meninges; Autoradiography; (Human tissue) 
1. INTRODUCTION 
Many biochemical and immunohistochemical 
studies have shown that opioid peptides are widely 
distributed in the central [l-3] and peripheral ner- 
vous [4] systems as well as in plasma [5,6] or 
cerebrospinal fluid [7,8]. 
Several enzymes in nervous tissue (neutral en- 
dopeptidase [9], aminopeptidases [lo], dipep- 
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The distribution of this enzyme in the nervous 
system, including the spinal cord, has recently been 
described [151. However, enkephalinase isalso pre- 
sent in several non-nervous tissues such as lung, 
kidney [ 161 or plasma [17]. Recently, neutral en- 
dopeptidase immunoreactivity has been evidenced 
in the pia mater of both cortex and spinal cord of 
pig 1181. 
Abbreviations: NEP, neutral endopeptidase; ACE, Here, we report the localisation of binding sites 
angiotensin-converting enzyme; HACBO-Gly, [(2Rs)- for the enkephalinase inhibitor [3H]HACBO-Gly 
3-hydroxyaminocarbonyl-2-benzyl-l-oxopropyl]glycine in meninges of human and rat. Because the men- 
tidylaminopeptidase [ 1 I]) are known to hydrolyze 
enkephalins. Neutral endopeptidase 24.11, often 
designated enkephalinase 191, has been implicated 
in the enkephalin inactivation both in vitro and in 
vivo [12,13] and pharmacological studies using 
specific inhibitors demonstrate its importance in 
the control of opioid peptide-mediated analgesia 
(review [14]). 
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inges form a barrier which protects the brain and 
spinal cord, it was of interest to explore also the 
possible occurrence of other peptidases and their 
relationship with neuropeptidergic systems. 
mesh (Waters Associates) as in [22]. The activity 
inhibited by low5 M thiorphan was considered as 
NEP activity [13]. 
2.3.2. Assay for aminopeptidases 
2. MATERIALS AND METHODS 
2.1. Chemicals 
Captopril and bestatin were a generous gift from 
Roger Bellon Laboratories. Thiorphan, retrothior- 
phan and 3H-labelled N-[(RS)-3-hydroxyamino- 
carbonyl-2-benzyl- 1-oxopropyl]glycine (I’W- 
HACBO-Gly) 45 Ci/mmol were synthesized as 
described [13,19,20]. [3H][Leu]enkephalin (50 Ci/ 
mmol) and [3H][D-Ala2,Leu5]enkephalin (38 Ci/ 
mmol) were from CEA. Other chemicals were 
purchased from Bachem (Switzerland). 
The assay was as above except that the substrate 
used was [3H][Leu]enkephalin (10 nM) in the 
presence of 10e5 M thiorphan and 10F5 M cap- 
topril. The activity inhibited by lo-’ M bestatin 
was considered as aminopeptidase activity [23]. 
2.3.3. Assay for ACE 
2.2. Crude membrane fraction preparation 
Human dura mater, pia mater and spinal cord 
were dissected and homogenized in 10 vols of 
5 mM Tris-HCl, 0.32 M sucrose (pH 7.4) using a 
Polytron grinder. The homogenate was centri- 
fuged for 40 min at 90000 x g (4’C), the superna- 
tant discarded and the pellet washed in 50 mM 
Tris-HCI (pH 7.4). The resultant pellet was 
resuspended in the same buffer and aliquots taken 
for enzyme assays. 
ACE activity was measured using 50 pM Z-Phe- 
His-Leu as substrate. The incubation was carried 
out for 60 min at 37°C in 50 mM Tris-HCl (pH 
7.4) buffer with or without 10m5 M captopril in a 
final volume of 250~1. The reaction was stopped 
by boiling for 5 min. The concentration of the His- 
Leu metabolite was determined following the 
fluorimetric assay in [24] with a Perkin Elmer 
MPF 44A spectrofluorimeter (excitation 365 nm, 
emission 500 nm). 
2.3.4. Assay for [Leulenkephalin degradation 
Rat tissues (male Sprague-Dawley, 150 g) were 
prepared in the ‘same manner except that cen- 
trifugations were carried out for 15 min at 10000 
X g (Sigma centrifuge). 
Protein determinations were carried out by the 
method of Lowry et al. [21]. 
The assay was as for neutral endopeptidase x- 
cept that the substrate used was 20 nM 
[3H][Leu]enkephalin. Crude membrane fractions 
were preincubated with 10e7. M retrothiorphan or 
10s5 M bestatin or 10e6 M captopril. The amount 
of enkephalin degraded in 30 min without in- 
hibitors was defined as 100% degradation. 
2.4. Autoradiographic studies 
2.3. Enzyme assays 
2.3.1. Assay for NEP 24.11 
Crude membrane fractions were preincubated 
for 15 min at 25 “C in 50 mM Tris-HCl (pH 7.4) 
buffer with low5 M bestatin, lo-’ M captopril in 
the presence or absence of 10m5 M thiorphan. The 
reaction was started by the addition of [3H][D- 
Ala2,Leu5]enkephalin (20 nM final concentration 
in a total volume of 100~1). 
Human spinal cord was dissected and frozen in 
isopentane at - 40°C. Sections (20 pm) were cut in 
a cryostat at - 2O”C, thaw-mounted on 0.1% 
polylysine (PM > 150000 Sigma) coated slides. Sec- 
tions were incubated in 50 mM Tris-HCl buffer 
(pH 7.4) at 25°C for 60 min with 3 nM 
[3H]HACBO-Gly in the presence or absence of 
1 PM thiorphan, rinsed in 6 changes of Tris buffer 
at 4°C and dried. Autoradiograms were generated 
by apposition on LKB ultrofilm for lo-12 weeks. 
3. RESULTS 
After 30 min at 25”C, the reaction was stopped 3.1. Autoradiographic studies 
by addition of 0.5 M HCl and the metabolites As clearly illustrated in fig. 1, [3H]HACBO-Gly- 
formed were measured by liquid scintillation spec- binding sites of human spinal cord were localized 
trometry after separation on Porapak Q 100-200 in the substantia gelatinosa of the dorsal horn. 
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Table 1 
Various enzymatic activities on meninges and whole spinal cord of human and rat 
May 1987 
Enkephalinase 
(fmol/mg 
per min) 
Amino- 
peptidases 
(fmol/mg 
per min) 
ACE 
(mmol/mg 
per min) 
Human tissue dura mater 230 86 0.40 
pia mater 30 66 0.77 
spinal cord 0.6 39 0.18 
Rat tissue dura mater 26 168 0.67 
pia mater 20 173 1.92 
spinal cord 7 84 0.06 
Enzymatic assays were as described in section 2. Values are means of at least three 
independent determinations 
This localization was similar to that previously 
observed in rat spinal cord [ 161. However, a very 
dense labelling of [3H]HACBO-Gly was also found 
around the tissue corresponding to meninges 
coupled to the spinal cord. This labelling was 
g-fold higher than that observed in the substantia 
gelatinosa nd about 50-90-fold higher than in the 
rest of the spinal cord. [3H]HACBO-Gly labelling 
Fig.1. Film autoradiograph from frozen human spinal 
cord sections. 20 pm sections of human spinal cord (17 
months old) were incubated with 3 nM [3H]HACBG 
Gly as a marker of enkephalinase sites. Black areas 
(arrowheads) correspond to high densities of binding 
sites at the level of the dura mater. A lower labelling is 
localized in the superficial layers of the dorsal horn. 
Bar = 1 mm. 
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in meninges as well as in the laminae II was 
abolished by the presence of 1 fiM thiorphan, in- 
dicating that this binding represents specific 
binding to NEP 24.11 [13]. 
The same pattern was observed in transverse sec- 
tions of whole rat. The spinal cord and the brain 
were entirely surrounded by a very dense 
homogeneous labelling (not shown). 
3.2. Enzymatic activities in meninges 
The distribution of enkephalinase in the dif- 
ferent meninges was evaluated by enzymatic assays 
performed in dura mater, pia mater and spinal 
cord of human and rat tissue after careful dissec- 
tion. Moreover, the possible occurrence of other 
peptidases uch as ACE and aminopeptidases was 
investigated using selective assays (table 1). 
NEP, the activity of which was characterized as 
thiorphan-sensitive [3H][D-Ala2,Leu5]enkephalin 
hydrolysis, was present in high concentrations in 
the dura mater and pia mater representing respec- 
tively about 300- and 50-fold the concentration 
observed in the whole spinal cord. 
Bestatin-sensitive aminopeptidase activities 
(ICSO = 10e6 M) were distributed in the three 
tissues with only slight differences; the hydrolyzing 
capacity of the dura mater was only 2.2-fold 
greater than that of whole spinal cord. ACE activi- 
ty was the highest in the pia mater and 4.2-fold 
superior to that of spinal cord. 
In rat tissue, the total concentrations of the three 
enzymatic activities were very different from those 
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Fig.2. [Leulenkephalin degradation in human meninges 
was measured in the presence of 10 nM 
[3H][Leu]enkephalin under experimental conditions 
which gave about 10% of degraded substrate. The 
enkephalin degraded in 30 min was defined as 100% of 
degradation. The proportion of degradation due to each 
enzyme was evaluated by measuring hydrolysis in the 
presence of specific inhibitors: retrothiorphan, lo-’ M 
(enkephalinase); or bestatin, 10d5 M (aminopeptidases); 
or captopril, lO-‘j M (ACE). NEP, neutral 
endopeptidase; AP, aminopeptidase; ACE, angiotensin 
converting enzyme. 
observed in human tissue. The relative distribu- 
tions of enkephalinase, aminopeptidases and ACE 
between the three tissues studied were similar in rat 
and in human (table 1) while in rat enkephalinase 
activity in the dura mater was only 3.7-fold greater 
than in the nervous tissue of the spinal cord. 
3.3. [Leulenkephalin-hydrolyzing capacity of 
meninges 
We have studied the relative capacity of enzymes 
present in rat and human meninges to hydrolyze 
[Leulenkephalin. The characterization of en- 
zymatic activities was defined by the use of specific 
inhibitors: retrothiorphan [ 191, bestatin and cap- 
topril for enkephalinase, aminopeptidases and 
ACE, respectively. 
As shown in fig.2, in human dura mater 45% of 
the hydrolysis of [Leulenkephalin was due to NEP 
and 38% to bestatin-sensitive aminopeptidases. In 
human pia mater, the proportion of substrate 
hydrolysis due to enkephalinase was inferior to 
that measured in the dura mater (table l), while 
aminopeptidase activity was similar in both tissues. 
In rat tissue, these proportions were completely 
different since in dura mater, as well as in spinal 
cord, aminopeptidase activities were responsible 
for 52 and 8 1% respectively of the total enkephalin 
degradation. ACE hydrolyzed enkephalin with a 
low efficiency in human tissue and was not 
demonstrated in rat tissue. Furthermore, in both 
cases, a small residual enzymatic activity which 
was insensitive to retrothiorphan, captopril and 
bestatin remained. 
4. DISCUSSION 
The present paper demonstrates the presence of 
NEP 24.11 ‘enkephalinase’, ACE and amino- 
peptidase-like activity in human and rat meninges. 
Human dura mater contains a very high concentra- 
tion of NEP in comparison to the whole spinal 
cord. Enkephalinase was defined both by the 
specific binding of [3H]HACBO-Gly [20] and by 
the sensitivity of [D-Ala2,LeuS]enkephalin and 
[Leulenkephalin hydrolysis to the NEP inhibitors 
thiorphan and retrothiorphan [ 13,191. 
To our knowledge, the presence of enkephalins 
in the meninges has not been described. This situa- 
tion can be compared to that found in kidney, 
lymph and lung which also possess a very high level 
of enkephalinase [9,17] and no enkephalin fibers. 
Regarding enkephalins and possibly other pep- 
tides, the enkephalinase activity could represent a 
clearing system similar to that of venous plasma 
1251. In this sense, enkephalinase in dura mater 
could actually be localized in a structure com- 
parable to the arachnoid villus of the brain, which 
resorbs cerebrospinal fluid back into the 
bloodstream. The presence of other peptidases 
such as ACE and aminopeptidases in meninges 
supports this hypothesis. Collectively, these en- 
zymes could ensure complete hydrolysis of pep- 
tides filtered by the meninges. Likewise, in pia 
mater these enzymes could represent the same 
clearing system for the fluid entering into the cen- 
tral nervous system. 
Both the dura and pia mater have an abundant 
innervation. Fine terminal branches of the sym- 
pathetic nervous system form elaborate plexus in 
the blood vessels and many free sensory endings 
are also present in the outermost layer of the blood 
vessels. Thus, some data have shown that 
substance P is a neurotransmitter present within 
pia mater of various species [26]. For these 
reasons, it is possible that enkephalinase observed 
in meninges is associated with neuronal structures 
and plays an additional role in the neurotransmis- 
sion process as is the case in the central nervous 
system. 
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In conclusion, the large amounts of various pep- 
tidases in structures controlling exchanges between 
brain and biological fluids such as meninges, 
choroid plexus [15,18] as well as epithelium of 
brain capillaries [27] very likely serve to control the 
level of neuropeptides in the CNS. 
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